nach oben

Erschienen in:

07.10.2019 | Original Article

Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome

verfasst von: Dr. Khaled Elsayad, MD, Dr. Kai Kroeger, Prof. Dr. Burkhard Greve, Dr. Christos Moustakis, Prof. Dr. Chalid Assaf, Prof. Dr. Rudolf Stadler, Prof. Dr. Georg Lenz, Dr. Carsten Weishaupt, Prof. Dr. Hans Theodor Eich

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Total skin electron beam therapy (TSEBT) has proved to be a safe and effective treatment for cutaneous T‑cell lymphomas. Here, we examined the impact of this treatment on patient quality of life and outcome.

Patients and methods

Forty-four patients with mycosis fungoides (MF) or Sezary syndrome (SS) received 48 TSEBT courses with a median dose of 12 Gy within the past 8 years at our institute. Patient and treatment characteristics for these cases as well as the impact of TSEBT on quality of life and duration of response were retrospectively analyzed and compared.

Results

The median modified Severity-Weighted Assessment Tool score before the start of TSEBT was 44. The overall response rate was 88%, with a complete response (CR) rate of 33%. The median follow-up period was 13 months. The median duration of response (DOR) and progression-free survival (PFS) for the entire cohort were 10 months and 9 months, respectively. Patient-reported symptom burden was measured with the Dermatological Life Quality Index and Skindex-29 questionnaires. The mean symptom reductions were 6 ± 8 (P = 0.005) and 21 ± 24 (P = 0.002), respectively. In the Functional Assessment of Cancer Therapy-General Assessment, significant improvements in the emotional (P = 0.03) domains were observed after TSEBT. Patients who received maintenance or adjuvant treatments had a longer PFS (P = 0.01).

Conclusion

TSEBT improved disease symptoms and significantly improved emotional domains of patients’ quality of life in patients with MF or SS. In addition, our results indicate that maintenance or adjuvant therapy after TSEBT may improve the PFS.

Stadler R, Stranzenbach R (2018) Molecular pathogenesis of cutaneous lymphomas. Exp Dermatol 27(10):1078–1083. https://doi.org/10.1111/exd.13701 CrossRefPubMed

Leuchte K, Schlaak M, Stadler R et al (2017) Innovative treatment concepts for cutaneous T‑cell Lymphoma based on microenvironment modulation. Oncol Res Treat 40(5):262–269. https://doi.org/10.1159/000472257 CrossRefPubMed

Harrison C, Young J, Navi D et al (2011) Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 81(4):e651–e657. https://doi.org/10.1016/j.ijrobp.2011.01.023 CrossRefPubMed

Hoppe RT, Harrison C, Tavallaee M et al (2015) Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol 72(2):286–292. https://doi.org/10.1016/j.jaad.2014.10.014 CrossRefPubMed

Kamstrup MR, Gniadecki R, Iversen L et al (2015) Low-dose (10-Gy) total skin electron beam therapy for cutaneous T‑cell lymphoma: an open clinical study and pooled data analysis. Int J Radiat Oncol Biol Phys 92(1):138–143. https://doi.org/10.1016/j.ijrobp.2015.01.047 CrossRefPubMed

Elsayad K, Kriz J, Moustakis C et al (2015) Total skin electron beam for primary cutaneous T‑cell lymphoma. Int J Radiat Oncol Biol Phys 93(5):1077–1086. https://doi.org/10.1016/j.ijrobp.2015.08.041 CrossRefPubMed

Morris S, Scarisbrick J, Frew J et al (2017) The results of low-dose total skin electron beam radiation therapy (TSEB) in patients with mycosis fungoides from the UK cutaneous lymphoma group. Int J Radiat Oncol Biol Phys 99(3):627–633. https://doi.org/10.1016/j.ijrobp.2017.05.052 CrossRefPubMed

Kroeger K, Elsayad K, Moustakis C et al (2017) Niedrigdosis-Ganzhautelektronenbestrahlung bei Patienten mit kutanen Lymphomen : Minimales Risiko für akute Toxizitäten (Low-dose total skin electron beam therapy for cutaneous lymphoma : Minimal risk of acute toxicities). Strahlenther Onkol 193(12):1024–1030. https://doi.org/10.1007/s00066-017-1188-8 CrossRefPubMed

Elsayad K, Oertel M, Haverkamp U et al (2017) The effectiveness of radiotherapy for leukemia cutis. J Cancer Res Clin Oncol 143(5):851–859. https://doi.org/10.1007/s00432-016-2338-6 CrossRefPubMed

10.

Prince HM, Kim YH, Horwitz SM et al (2017) Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T‑cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 390(10094):555–566. https://doi.org/10.1016/S0140-6736(17)31266-7 CrossRefPubMed

11.

Khodadoust M, Rook AH, Porcu P et al (2016) Pembrolizumab for treatment of relapsed/refractory mycosis fungoides and sezary syndrome: clinical efficacy in a Citn Multicenter phase 2 study. Blood 128(22):181CrossRef

12.

Jain S, Zain J, O’Connor O (2012) Novel therapeutic agents for cutaneous T‑Cell lymphoma. J Hematol Oncol 5:24. https://doi.org/10.1186/1756-8722-5-24 CrossRefPubMedPubMedCentral

13.

Trautinger F, Eder J, Assaf C et al (2017) European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome—Update 2017. Eur J Cancer 77:57–74. https://doi.org/10.1016/j.ejca.2017.02.027 CrossRefPubMed

14.

Heumann TR, Esiashvili N, Parker S et al (2015) Total skin electron therapy for cutaneous T‑cell lymphoma using a modern dual-field rotational technique. Int J Radiat Oncol Biol Phys 92(1):183–191. https://doi.org/10.1016/j.ijrobp.2014.11.033 CrossRefPubMedPubMedCentral

15.

Selman LE, Beynon T, Radcliffe E et al (2015) ‘We’re all carrying a burden that we’re not sharing’: a qualitative study of the impact of cutaneous T‑cell lymphoma on the family. Br J Dermatol 172(6):1581–1592. https://doi.org/10.1111/bjd.13583 CrossRefPubMed

16.

Dippel E, Assaf C, Becker JC et al (2018) S2k guidelines—cutaneous lymphomas update 2016—part 2: treatment and follow-up (ICD10 C82—C86). J Dtsch Dermatol Ges 16(1):112–122. https://doi.org/10.1111/ddg.13401 CrossRefPubMed

17.

Molloy K, Evison F, Peng C et al (2018) Quality of life in patients with mycosis fungoides and Sezary syndrome is significantly worse in female patients, Sézary syndrome and those with more extensive skin involvement. Eur J Cancer 101:S39. https://doi.org/10.1016/j.ejca .2018.07.310CrossRef

18.

Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)— a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210–216CrossRefPubMed

19.

Chren MM, Lasek RJ, Quinn LM et al (1996) Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 107(5):707–713CrossRefPubMed

20.

Yost KJ, Thompson CA, Eton DT et al (2012) The Functional Assessment of Cancer Therapy—General (FACT-G) is valid for monitoring quality of life in non-Hodgkin lymphoma patients. Leuk Lymphoma 54(2):290–297. https://doi.org/10.3109/10428194.2012.711830 CrossRefPubMedPubMedCentral

21.

Olsen EA, Whittaker S, Kim YH et al (2011) Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma task force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29(18):2598–2607. https://doi.org/10.1200/JCO.2010.32.0630 CrossRefPubMedPubMedCentral

22.

Elsayad K, Moustakis C, Simonsen M et al (2018) In-vivo dosimetric analysis in total skin electron beam therapy. Phys Imaging Radiat Oncol 6:61–65. https://doi.org/10.1016/j.phro.2018.05.002 CrossRefPubMedPubMedCentral

23.

Elsayad K, Susek KH, Eich HT (2017) Total skin electron beam therapy as part of multimodal treatment strategies for primary cutaneous T‑cell lymphoma. Oncol Res Treat 40(5):244–252. https://doi.org/10.1159/000475634 CrossRefPubMed

24.

Simontacchi G, Lo Russo M, Marrazzo L et al (2018) Low dose total skin irradiation followed by maintenance with oral bexarotene in mycosis fungoides. Radiother Oncol 127:376–S376CrossRef

25.

Ko EC, Formenti SC (2018) Radiotherapy and checkpoint inhibitors: a winning new combination? Ther Adv Med Oncol 10:1758835918768240. https://doi.org/10.1177/1758835918768240 CrossRefPubMedPubMedCentral

26.

An Y, Jiang W, Andraos TY et al (2019) Multi-institutional Investigation: circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiother Oncol 131:88–92. https://doi.org/10.1016/j.radonc.2018.12.003 CrossRefPubMed

27.

Lesokhin AM, Ansell SM, Armand P et al (2016) Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol 34(23):2698–2704. https://doi.org/10.1200/JCO.2015.65.9789 CrossRefPubMedPubMedCentral

28.

Khodadoust MS, Rook AH, Porcu P et al (2018) Pembrolizumab in mycosis fungoides and Sézary syndrome: updated results of the CITN multicenter Phase 2 study. Eur J Cancer 101:S37. https://doi.org/10.1016/j.ejca .2018.07.304CrossRef

29.

Battistella M, Janin A, Jean-Louis F et al (2016) KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma. Br J Dermatol 175(2):325–333. https://doi.org/10.1111/bjd.14626 CrossRefPubMed

30.

Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M et al (2019) IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T‑cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol 20(8):1160–1170CrossRefPubMed

31.

Kim YH, Bagot M, Pinter-Brown L et al (2018) Mogamulizumab versus vorinostat in previously treated cutaneous T‑cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 19(9):1192–1204. https://doi.org/10.1016/S1470-2045(18)30379-6 CrossRefPubMed

32.

Rückert M, Deloch L, Fietkau R et al (2018) Immunmodulierende Eigenschaften von Radiotherapie als Basis für wohldurchdachte Radioimmuntherapien (Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies). Strahlenther Onkol 194(6):509–519. https://doi.org/10.1007/s00066-018-1287-1 CrossRefPubMed

33.

Dabaja B (2017) Renaissance of low-dose radiotherapy concepts for cutaneous lymphomas. Oncol Res Treat 40(5):255–260. https://doi.org/10.1159/000470845 CrossRefPubMed

34.

Moritz RKC, Ditschkowski M, Klemke C‑D et al (2014) Allogeneic stem cell transplantation in patients with aggressive primary cutaneous T‑cell lymphoma—a case series of the ADF working group “cutaneous lymphomas”. J Dtsch Dermatol Ges 12(1):39–46. https://doi.org/10.1111/ddg.12212 CrossRefPubMed

35.

Polansky M, Talpur R, Daulat S et al (2015) Long-term complete responses to combination therapies and allogeneic stem cell transplants in patients with Sezary syndrome. Clin Lymphoma Myeloma Leuk 15(5):e83–e93. https://doi.org/10.1016/j.clml.2014.09.013 CrossRefPubMed

Titel: Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome
verfasst von: Dr. Khaled Elsayad, MD
Dr. Kai Kroeger
Prof. Dr. Burkhard Greve
Dr. Christos Moustakis
Prof. Dr. Chalid Assaf
Prof. Dr. Rudolf Stadler
Prof. Dr. Georg Lenz
Dr. Carsten Weishaupt
Prof. Dr. Hans Theodor Eich
Publikationsdatum: 07.10.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 1/2020
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-019-01517-7

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome

Abstract

Purpose

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Modulation of radiation-induced oral mucositis (mouse) by dermatan sulfate: effects on differentiation processes

Role of upper abdominal reirradiation for gastrointestinal malignancies: a systematic review of cumulative dose, toxicity, and outcomes on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Variability in lymph node irradiation in patients with breast cancer—results from a multi-center survey in German-speaking countries

Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation

Durvalumab nach Radiochemotherapie beim lokal fortgeschrittenen inoperablen NSCLC – ein Sprung nach vorn

Bevacizumab as a treatment option for radiation necrosis after cranial radiation therapy: a retrospective monocentric analysis

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie